Market Overview

GenMark, T2 And Accelerate Diagnostics Impress Analysts At Microbiology Forum

Share:
GenMark, T2 And Accelerate Diagnostics Impress Analysts At Microbiology Forum

Canaccord Genuity provided some remarks on three companies after attending the "American Society for Microbiology" forum. According to the report published Monday, the Canaccord Genuity analysts are positive on GenMark Diagnostics, Inc (NASDAQ: GNMK) and T2 Biosystems Inc (NASDAQ: TTOO), and they expect Accelerate Diagnostics Inc (NASDAQ: AXDX) to remain a key player to follow in 2016–2017.

Related Link: NantHealth Uses The Cloud To Offer Value, Drive Earnings

The analysts noted it is possible to see "additional consolidation as upstart growth companies enter new verticals, or eat into the shares of the incumbents," despite a strong competition in infectious disease. Strong traffic was noticed in booths of all three companies during the exhibition.

At Time Of Writing...

  • Accelerate was down 4.41 percent at $14.30 on the day.
  • T2 was down 2.47 percent at $8.29.
  • GenMark was down 3.95 percent at $8.02.

Latest Ratings for AXDX

DateFirmActionFromTo
Sep 2019DowngradesNeutralUnderweight
Nov 2018DowngradesOverweightNeutral
May 2018Initiates Coverage OnHold

View More Analyst Ratings for AXDX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Events Analyst Ratings Movers

 

Related Articles (GNMK + AXDX)

View Comments and Join the Discussion!

SolarCity Won't Get Burned By Brexit, Analysts Say

GW Pharmaceuticals Surrenders Big Pre-Market Gains